Reported about 22 hours ago
Gilead Sciences has announced an additional $11 billion investment plan in the United States to enhance domestic manufacturing and research, responding to President Trump's tariff policies. This funding will supplement a previously planned $21 billion investment aimed at increasing U.S. production capabilities and is expected to create 800 new direct jobs, supporting over 2,200 indirect jobs by 2028. Gilead's initiatives align with recent moves by other major drugmakers to bolster their presence in the U.S. amidst growing tariff threats.
Source: YAHOO